Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Voxilaprevir + SOF/VEL in Genotype 1 HCV
NCT02378935Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Feb 2015
- Primary completion
- Feb 2016
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial of voxilaprevir in hepatitis C (HCV) (10 arms), sponsored by Gilead Sciences. Primary endpoints: Sustained Virologic Response 12 Weeks After Discontinuation of Therapy and Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event up to 12 weeks. Started Feb 2015; status: completed.
02
Drugs
voxilaprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02378935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02378935.